What does Labotoxico do?

Labotoxico is a shop in Damme. Public Limited, started on 20 November 1987, 1 establishment.

What is the address of Labotoxico?

The registered office of Labotoxico is located at Dorpsstraat 110, 8340 Damme.

Is Labotoxico still active?

Yes. According to the CBE (29 October 2026) Labotoxico is active, legal situation “Normale toestand”, started on 20 November 1987.

Is Labotoxico registered on Peppol?

Yes, Labotoxico is registered on the Peppol network with ID 0208:0432685722.

What is the enterprise number of Labotoxico?

The enterprise number of Labotoxico is BE0432685722.

When was Labotoxico founded?

Labotoxico was founded on 20 November 1987.

Who are the directors of Labotoxico?

According to the 2025 annual accounts, the directors of Labotoxico are: Anne Leenesonne, APOCHEM NV.

Is Labotoxico a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 November 1987; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Labotoxico make in 2025?

Labotoxico recorded a loss after taxes of € 28,201 in financial year 2025.

What is the revenue of Labotoxico?

As a small company, Labotoxico is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 134,214.

How many employees does Labotoxico have?

According to the 2025 annual accounts, Labotoxico has 0 full-time equivalents (FTE).

Labotoxico (Public Limited) - Damme - BE0432685722

Dossier Labotoxico, printed on 29 October 2026 from databakkes.be/en/0432685722/labotoxico. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

Labotoxico from Damme, company number BE0432685722, closed financial year 2025 with a result of € -28,201 after tax. For that financial year Labotoxico recorded a gross margin of € 134,214 and equity of € 2.5 million. Compared with financial year 2024, the result moved from € -181,887 to € -28,201. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on January 26, 2026.

What it is worth Healthy

€ 2.5 million

▼ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -28,201

▲ 84 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 114,519

▲ 62% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 2.4 million.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 1,102

▲ 25% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 30,788

▼ 31% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 15 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 641,036

▼ 6% vs 2024

€ 44,046 is repaid this year. At this pace the long-term loan is gone in ≈ 15 years.

Owed to suppliers

€ 76,175

▲ 77% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 100,484 Gross margin 2022: € 100,484 First fiscal year in the series	€ 63,500 Gross margin 2023: € 63,500 ▼ 37% vs 2022 (€ 100,484) Unfavourable step	€ 39,108 Gross margin 2024: € 39,108 ▼ 38% vs 2023 (€ 63,500) Unfavourable step	€ 134,214 Gross margin 2025: € 134,214 ▲ 243% vs 2024 (€ 39,108) Favourable step	▲ 243%
Profit after taxes	€ 20,798 Profit after taxes 2022: € 20,798 First fiscal year in the series	€ -70,024 Profit after taxes 2023: € -70,024 ▼ € 90,822 vs 2022 (€ 20,798) Unfavourable step	€ -181,887 Profit after taxes 2024: € -181,887 ▼ € 111,862 vs 2023 (€ -70,024) Unfavourable step	€ -28,201 Profit after taxes 2025: € -28,201 ▲ € 153,686 vs 2024 (€ -181,887) Favourable step	▲ € 153,686
Equity	€ 2,759,711 Equity 2022: € 2,759,711 First fiscal year in the series	€ 2,689,686 Equity 2023: € 2,689,686 ▼ 3% vs 2022 (€ 2,759,711) Unfavourable step	€ 2,507,800 Equity 2024: € 2,507,800 ▼ 7% vs 2023 (€ 2,689,686) Unfavourable step	€ 2,479,599 Equity 2025: € 2,479,599 ▼ 1% vs 2024 (€ 2,507,800) Unfavourable step	▼ 1%
Total debts	€ 608,431 Total debts 2022: € 608,431 First fiscal year in the series	€ 1,124,397 Total debts 2023: € 1,124,397 ▲ 85% vs 2022 (€ 608,431) Unfavourable step	€ 1,395,602 Total debts 2024: € 1,395,602 ▲ 24% vs 2023 (€ 1,124,397) Unfavourable step	€ 1,345,540 Total debts 2025: € 1,345,540 ▼ 4% vs 2024 (€ 1,395,602) Favourable step	▼ 4%
Cash	€ 161,874 Cash 2022: € 161,874 First fiscal year in the series	€ 80,940 Cash 2023: € 80,940 ▼ 50% vs 2022 (€ 161,874) Unfavourable step	€ 70,810 Cash 2024: € 70,810 ▼ 13% vs 2023 (€ 80,940) Unfavourable step	€ 114,519 Cash 2025: € 114,519 ▲ 62% vs 2024 (€ 70,810) Favourable step	▲ 62%
Land & buildings	€ 1,631,695 Land & buildings 2022: € 1,631,695 First fiscal year in the series	€ 2,281,989 Land & buildings 2023: € 2,281,989 ▲ 40% vs 2022 (€ 1,631,695) Unchanged	€ 2,417,377 Land & buildings 2024: € 2,417,377 ▲ 6% vs 2023 (€ 2,281,989) Unchanged	€ 2,297,372 Land & buildings 2025: € 2,297,372 ▼ 5% vs 2024 (€ 2,417,377) Unchanged	▼ 5%
Retained profit	€ 2,697,711 Retained profit 2022: € 2,697,711 First fiscal year in the series	€ 2,627,686 Retained profit 2023: € 2,627,686 ▼ 3% vs 2022 (€ 2,697,711) Unfavourable step	€ 2,445,800 Retained profit 2024: € 2,445,800 ▼ 7% vs 2023 (€ 2,627,686) Unfavourable step	€ 2,417,599 Retained profit 2025: € 2,417,599 ▼ 1% vs 2024 (€ 2,445,800) Unfavourable step	▼ 1%
Dividend	€ 35,000 Dividend 2022: € 35,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 35,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 365,385 Bank debt 2022: € 365,385 First fiscal year in the series	€ 567,778 Bank debt 2023: € 567,778 ▲ 55% vs 2022 (€ 365,385) Unfavourable step	€ 683,382 Bank debt 2024: € 683,382 ▲ 20% vs 2023 (€ 567,778) Unfavourable step	€ 641,036 Bank debt 2025: € 641,036 ▼ 6% vs 2024 (€ 683,382) Favourable step	▼ 6%
Balance sheet total	€ 3,631,929 Balance sheet total 2022: € 3,631,929 First fiscal year in the series	€ 4,065,919 Balance sheet total 2023: € 4,065,919 ▲ 12% vs 2022 (€ 3,631,929) Unchanged	€ 4,143,360 Balance sheet total 2024: € 4,143,360 ▲ 2% vs 2023 (€ 4,065,919) Unchanged	€ 4,053,220 Balance sheet total 2025: € 4,053,220 ▼ 2% vs 2024 (€ 4,143,360) Unchanged	▼ 2%

Key figures of Labotoxico, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to Labotoxico?

What happened at Labotoxico in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Anne Leenesonne stepped down as director. NBB
2029 APOCHEM NV stepped down as director. NBB
Jan 26, 2026 New annual accounts for financial year 2025: loss of € 28,201. Source: NBB ↗
2017 Anne Leenesonne became a director. NBB
2017 APOCHEM NV became a director. NBB
Jan 13, 1988 New establishment in Damme. KBO
Nov 20, 1987 Start of the company according to the CBE. KBO

In short

From € 20,798 profit in 2022 to € 28,201 loss in 2025.

Paid € 7,071 in corporate taxes since 2022.

Best year ever: 2022, with € 20,798 profit.

Paid out € 35,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

APOCHEM 30%

The stake of APOCHEM comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Labotoxico

Biocontrol 100%

The shares are held by APOCHEM (30%). It owns 100% of Biocontrol itself.

Directors

According to the 2025 annual accounts

Anne Leenesonne

Director

Also active at: Apotheek Leenesonne, APOCHEM

since 2017 · until 2029

APOCHEM NV

Director · represented by Jan Cordonnier

Also active at: Apotheek Leenesonne

since 2017 · until 2029

Shareholders

APOCHEM

30%

Participations

Biocontrol

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Dorpsstraat 110

8340 Damme

2.033.163.847

Dorpsstraat 106

8340 Damme

Active since 13 January 1988

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0432.685.722

VAT number

BE 0432.685.722

Registered office

Dorpsstraat 110, 8340 Damme

Names & denominations

Labotoxico

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

20 November 1987

Peppol

Active · Active since 21 Oct 2026

Activities · NACE

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Medische laboratoria

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen

Activiteiten van medische beeldvorming en medische laboratoria

Vervaardiging van medische en tandheelkundige instrumenten en benodigdheden

Handel in eigen onroerend goed

View on CBE Public ↗ Annual accounts (NBB) ↗

Labotoxico

Warning lights

Financials

What happened to Labotoxico?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions